The Technical Analyst
Altimmune Inc [ALT]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Altimmune Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-3.76% $11.26
Last updated: 3 jul 2022 - 19:20
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 486.65 mill |
| EPS: | -2.39 |
| P/E: | 0.000 |
| Earnings Date: | Aug 08, 2022 |
| SharesOutstanding: | 43.22 mill |
| Avg Daily Volume: | 1.304 mill |
| RATING 2022-07-01 |
|---|
| B+ |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$18.68 (65.92%) $7.42 |
| Date: 2022-07-03 |
| True Range Average |
|---|
|
+/- $0.999 ( +/- 8.87%) Range: 10.26 - 12.26 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-06-30 | Garg Vipin K | Sell | 3 007 | Common Stock, par value $0.0001 |
| 2022-06-29 | Roberts M Scot | Sell | 5 462 | Stock Options (option to buy) |
| 2022-06-29 | Roberts M Scot | Sell | 5 462 | Common Stock, par value $0.0001 |
| 2022-06-29 | Roberts M Scot | Buy | 5 462 | Common Stock, par value $0.0001 |
| 2022-06-27 | Roberts M Scot | Sell | 11 769 | Stock Options (option to buy) |
| INSIDER POWER |
|---|
| 41.52 |
| Last 100 transactions |
| Buy: 2 730 937 | Sell: 1 274 483 |
Forecast:
16:00 - $11.26
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $11.26
Forecast 2: 16:00 - $11.26
Forecast 3: 16:00 - $11.26
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $11.26 (-3.76% ) |
| Volume | 1.581 mill |
| Avg. Vol. | 1.304 mill |
| % of Avg. Vol | 121.26 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALT
15 Signals | Accuracy: 33.33% | Accuracy Buy: 37.50% | Accuracy Sell: 28.57%
Avg return buy: -0.34 % | Avg return sell: 0.59 %
$1 invested is now $0.97 or -2.71% since 30-06-22
| Date | Signal | @ | Closed | % | Jun 30 - 09:30 | sell | $11.66 | $11.58 @ Jun 30 - 12:41 | -0.69% |
|---|---|---|---|---|
| Jun 30 - 09:29 | buy | $11.77 | $11.66 @ Jun 30 - 09:30 | -0.93% |
ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
Latest Press Releases
2022-06-17 07:30:00 - Press Release
Altimmune Announces Oral Presentation Of Pemvidutide Clinical Data At Upcoming Easl International Liver Congress™ On June 25, 2022
Presentation to be highlighted in the best of international liver congress presentation to be highlighted in the best of international liver congress
2022-04-01 07:00:00 - Press Release
Altimmune Announces Initiation Of 48-week Phase 2 Momentum Trial Of Pemvidutide In Obesity
The company also announces completion of enrollment in 12-week, phase 1b trial of pemvidutide in subjects with non-alcoholic fatty liver disease (nafld) the company also announces completion of enrollment in 12-week, phase 1b trial of pemvidutide in subjects with non-alcoholic fatty liver disease (nafld)
2022-03-15 07:01:00 - Press Release
Altimmune Reports Fourth Quarter And Full Year 2021 Financial Results And Provides A Corporate Update
Data readouts from multiple clinical trials expected during the next 6 to 12 months
2022-01-31 07:00:00 - Press Release
Altimmune Announces Fda Clearance Of Pemvidutide (alt-801) Ind For Obesity
Enrollment in 48-week phase 2 clinical trial expected to begin in q1 2022 enrollment in 48-week phase 2 clinical trial expected to begin in q1 2022
2021-12-13 06:00:00 - Press Release
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Gaithersburg, md., dec. 13, 2021 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that the compensation committee of its board of directors granted equity awards under altimmune's 2018 inducement grant plan, as a material inducement to employ richard eisenstadt as altimmune's chief financial officer effective december 31, 2021. the equity awards were approved on december 9, 2021, in accordance with nasdaq listing rule 5635(c)(4).
Latest News
2022-06-30 10:58:24 - Zacks Investment Research
Is Altimmune (ALT) Outperforming Other Medical Stocks This Year?
Here is how Altimmune, Inc. (ALT) and Chinook Therapeutics (KDNY) have performed compared to their sector so far this year.
2022-06-28 20:18:49 - Seeking Alpha
Altimmune: Several Catalysts In 2 Large Market Indications This Year
Results from phase 1b NAFLD study using pemvidutide are to be released 2nd half of 2022;Q3 of 2022 will be 12-week data and Q4 of 2022 will be 24-week data. It is estimated that the global NASH market could be worth $20 billion by 2027.
2022-06-14 10:50:27 - Zacks Investment Research
Has Altimmune (ALT) Outpaced Other Medical Stocks This Year?
Here is how Altimmune, Inc. (ALT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.
2022-06-03 07:30:00 - GlobeNewsWire
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., June 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate at the following investor conferences in June 2022:
2022-05-31 07:30:00 - GlobeNewsWire
Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
GAITHERSBURG, Md., May 31, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of Medicine and Nutritional Science Director, Washington University School of Medicine, will deliver an oral presentation at the 82nd American Diabetes Association (ADA) Scientific Sessions, to be held in New Orleans, LA on June 3-7, 2022. Dr. Klein will present the results of Altimmune's recently completed Phase 1, first-in-human clinical trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
2022-05-20 07:30:00 - GlobeNewsWire
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5th Global NASH Congress on May 26-27, 2022, in London, UK. His presentation will provide an overview of pemvidutide, the Company's novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and NASH. Dr. Harris will also moderate a panel discussion on clinical endpoints in NASH trials.
2022-05-16 07:30:00 - GlobeNewsWire
Altimmune to Present at Upcoming Investor Conferences
GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate at the following investor conferences in May 2022:
2022-05-12 12:42:14 - Seeking Alpha
Altimmune, Inc. (ALT) CEO Vipin K. Garg on Q1 2022 Results - Earnings Call Transcript
Altimmune, Inc. (NASDAQ:ALT ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Vipin K. Garg – President and Chief Executive Officer Richard Eisenstadt – Chief Financial Officer Scot Roberts – Chief Scientific Officer Scott M.
2022-05-12 09:47:29 - Zacks Investment Research
Altimmune, Inc. (ALT) Reports Q1 Loss, Misses Revenue Estimates
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 22.81% and 98.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-03-15 13:59:06 - Seeking Alpha
Altimmune, Inc. (ALT) CEO Vipin Garg on Q4 2021 Results - Earnings Call Transcript
